NIH Highlighted Topic: Advancing Nanotechnology Research to Improve Diagnosis and Treatment Options
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing nanotechnology approaches to improve disease diagnosis, monitoring, drug delivery, and therapeutic development, with a particular emphasis on extracellular vesicles (EVs). This highlighted topic supports multidisciplinary research integrating nanotechnology, bioengineering, computational biology, AI, and advanced molecular analysis to accelerate the development of next-generation diagnostic and therapeutic platforms.
NIH is particularly interested in projects leveraging EVs and other nanoparticle technologies for early disease detection, biomarker discovery, targeted drug delivery, regenerative medicine, and precision therapeutics. Companies developing nanomedicine platforms, liquid biopsy technologies, engineered extracellular vesicles, targeted delivery systems, AI-enabled biomarker analytics, or advanced diagnostic tools may be strong candidates for funding.
Areas of interest include EV biogenesis and cargo analysis, multimodal biomarker discovery, nanoparticle-based diagnostics, engineered EV therapeutics, targeted drug delivery systems, cancer detection technologies, ophthalmic nanomedicine, regenerative therapeutics, digital flow cytometry, system-omics analysis, and computational modeling of nanoparticle behavior. NIH is also encouraging projects incorporating artificial intelligence, high-throughput assays, organoids, and New Approach Methodologies (NAMs) to better understand EV mechanisms and disease applications.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported primarily by the National Eye Institute (NEI) and the National Cancer Institute (NCI), both of which are seeking transformative nanotechnology innovations that improve diagnostics, disease monitoring, therapeutic delivery, and patient outcomes across cancer and ophthalmic diseases.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of nanotechnology platforms, extracellular vesicle technologies, diagnostics, biomarker systems, and targeted therapeutic delivery solutions.
Eligible activities may include:
Extracellular vesicle (EV) engineering and therapeutic platforms
Nanoparticle-based diagnostics and liquid biopsy technologies
AI and machine learning tools for biomarker discovery and analysis
Targeted drug delivery systems and controlled-release therapeutics
Cancer detection, monitoring, and prognosis platforms
Ophthalmic nanomedicine and regenerative therapeutic technologies
EV cargo characterization and multimodal omics analysis systems
High-throughput screening and digital flow cytometry technologies
Computational modeling and simulation of nanoparticle behavior
Stem cell-derived EV therapeutics and regenerative medicine platforms
Precision medicine and personalized therapeutic delivery systems
Organ-on-chip, organoid, and microphysiological research systems
Biomarker validation and treatment response monitoring technologies
Anti-inflammatory and neuroprotective therapeutic delivery platforms
Nanomaterials and bioengineered delivery vehicle development
Prototype development, translational studies, and validation research
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, laboratory testing, nanomaterial fabrication, AI model development, software engineering, cloud computing infrastructure, bioinformatics analysis, preclinical studies, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable nanotechnology or biotechnology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
